Staff:
Peter L. Gehlbach, M.D., Ph.D.
David C. Johns, Ph.D.
Beverly Pinn
Li Chen
Julia Haller, professor of opthamology at Johns Hopkins explains why controversy swirls around Lucentis, a new drug approved by the FDA for the treatment of macular degeneration.